Related Experiment Video
Updated: May 4, 2026

Autologous Microfractured and Purified Adipose Tissue for Arthroscopic Management of Osteochondral Lesions of the Talus
Published on: January 23, 2018
[Daily subcutaneous injection of teriparatide : the progress and current issues]
Shozo Yano1, Toshitsugu Sugimoto
1Department of Laboratory Medicine, Shimane University Faculty of Medicine, Japan.
Abstract:
Daily subcutaneous injection of teriparatide, which consists of 34 amino acids of N-terminal of parathyroid hormone, has been investigated as a therapy for osteoporosis. It has been used since 2010 in Japan. Since teriparatide markedly stimulates bone formation, its daily injection increases bone volume mainly at the cancellous bone and significantly reduces vertebral and non-vertebral fracture risk. Because of the limitation (2 years) of the use in the life span, sequential treatment following teriparatide is needed. When combined with an antiresorptive agent, teriparatide showed additive increase in bone mineral density. However, it remains uncertain which agent is the best for the combination and what schedule is the most effective. Since teriparatide reduces back pain and stimulates bone repair, it is suitable for patients with back pain or with severe osteoporosis.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Transdermal Drug Delivery Systems
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...

